---
layout: post
title: "Determination That BACTROBAN (Mupirocin) Nasal Ointment, 2%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-04 21:37:05 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-22682
original_published: 2025-12-12 00:00:00 +0000
significance: 8.00
---

# Determination That BACTROBAN (Mupirocin) Nasal Ointment, 2%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 12, 2025 00:00 UTC
**Document Number:** 2025-22682

## Summary

The Food and Drug Administration (FDA or Agency) has determined that BACTROBAN (mupirocin) nasal ointment, 2%, was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for mupirocin nasal ointment, 2%, if all other legal and regulatory requirements are met.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/12/2025-22682/determination-that-bactroban-mupirocin-nasal-ointment-2-was-not-withdrawn-from-sale-for-reasons-of)
- API: https://www.federalregister.gov/api/v1/documents/2025-22682

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
